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ASSeSSMent of RiSk ShARing AgReeMentS (RSAS) in Select globAl 
MARketS with SPecific focuS on ActivitieS SuRRounding 
iMMunoModulAtoRS
Napiecek D, Shah S, Ramesh V
Market Access Solutions LLC, Raritan, NJ, USA
Objectives: To understand current Risk Sharing Agreements (RSAs) for immu-
nomodulators for rheumatoid arthritis, psoriasis, and psoriatic arthritis in 11 mar-
kets aimed to optimize specific RSA strategies/ payer partnerships. MethOds: 
Review of publicly available health authority websites and peer-reviewed journals. 
Interviews with payers and stakeholders who influence RSA decisions and ex-
pharma executives for validation and gap filling. Results: USA manufacturers 
negotiate RSAs with private health insurers and states. Payers in USA integrate 
financial risks with manufacturers using outcome based agreements (OBAs). Canada 
established RSAs with Provinces and use financial based agreements (FBAs) but 
some are OBAs. France requires volume based FBAs for new high-priced therapies 
to limit budget impact. Germany uses FBAs at the sickness fund level rather than 
the Gemeinsamer Bundesausschuss (G-BA) level because sickness funds manage 
their own budgets. Some OBAs exist with clearly defined outcomes. Italy negotiates 
RSAs at the national level for new therapies entering the market ranging from FBAs 
to OBAs depending on the specific therapy and target patient population. Italy may 
also require manufacturers to incorporate drug monitoring registries in the RSA. In 
Spain performance based OBAs are used for new therapies with nominal additional 
benefit at the regional level with clearly established outcomes. Netherlands and 
Sweden use evidence development (CED) agreements for high priced products to 
generate cost effectiveness data. In Switzerland, RSAs are new and mostly FBAs 
and mainly for orphan disease therapies and off-label indications with price cap-
ping. In the UK,FBAs with few OBAs are used affecting product price but are not 
rebate based. Australian RSAs are mostly FBAs and are referred to as “Deeds of 
Agreement.” cOnclusiOns: With high-cost immunomodulators, authorities are 
shifting towards integrating RSAs in price negotiations to optimize budget expec-
tations prior to launch. Europe prefers FBAs to OBAs which often require clearly 
defined outcomes.
SYSteMic diSoRdeRS/conditionS – clinical outcomes Studies
PSY1
ASSociAtion of AdveRSe eventS And heAlth SeRvice uSAge with 
tAPentAdol PRolonged-ReleASe tReAtMent coMPARed with MoRPhine 
contRolled-ReleASe (cR) And oxYcodone cR: A uk PRiMARY cARe 
obSeRvAtionAl StudY
Baxter G1, Morgan CL2, Jenkins-Jones S2, Currie CJ2, Schultewolter D1
1Grünenthal, Stokenchurch, UK, 2Pharmatelligence, Cardiff, UK
Objectives: This study compared adverse outcomes and resource use in patients 
treated with tapentadol prolonged-release (PR) with those treated with morphine 
controlled-release (CR) and oxycodone CR. MethOds: Data were from the Clinical 
Practice Research Datalink, a database derived from UK primary-care. Patients pre-
scribed tapentadol PR between May 2011 and December 2014 were matched to two 
groups of controls treated with either morphine CR or oxycodone CR on gender, age, 
pain duration, pain site and aetiology, Charlson index and prior analgesia. Rates 
of adverse events (constipation and nausea/vomiting) were compared by adjusted 
hazard ratio (aHR). Rates of primary-care contacts, accident and emergency con-
tacts, outpatient clinic letters and, for a subset of patients linked to Hospital Episode 
Statistics (HES), inpatient admissions were compared using incident rate ratios (IRRs) 
derived from Poisson regression. Results: 1,176 patients prescribed tapentadol PR 
were identified; 1,103 (93.8%) had a pain diagnosis. Of these 789 (67.1%) were matched 
to morphine controls and 557 (47.4%) to oxycodone controls. Compared with con-
trols, adverse events with tapentadol PR treatment were reduced: aHR= 0.643 (95% 
CI 0.459–0.901; p= 0.010) versus morphine CR and 0.505 (0.335–0.763; p= 0.001) ver-
sus oxycodone CR. Compared with morphine CR, primary-care contacts (IRR= 0.817; 
0.786–0.850), accident and emergency attendance (0.699; 0.560–0.870) and outpatient 
letters (0.715; 0.543–0.939) were also reduced. For oxycodone CR, the respective figures 
were 0.776 (0.706–0.840), 0.840 (0.639–1.103) and 0.545 (0.400–0.739). For the subset of 
HES-linked patients the rates of inpatient admissions were 0.723 (0.590–0.884) and 
0.458 (0.357–0.585) vs. morphine CR and oxycodone CR, respectively. cOnclusiOns: 
Tapentadol PR was associated with significantly fewer adverse gastrointestinal events 
than morphine CR or oxycodone CR. There was also significantly reduced primary- 
and secondary-care resource use. As with all observational studies, potential bias 
due to residual confounding and confounding by indication should be considered.
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clinicAl And econoMic buRden of PulMonARY exceRbAtionS in 
PAtientS with cYStic fibRoSiS who ARe hoMozYgouS foR the f508del 
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Objectives: To assess the clinical and economic burden of pulmonary exacerba-
tions (PEx) in patients with cystic fibrosis (CF) and homozygous for the F508del 
CFTR gene mutation. MethOds: Medical chart data from patients with CF ≥ 12 
years old were collected in France, Germany, Italy, Spain, Australia and Canada. 
Demographics, clinical characteristics, and selected resource utilization were 
obtained for a 12-month baseline period and a follow-up period ranging from 2-36 
months. The frequency of PEx and associated resource utilization was assessed 
overall and by age (12-17, ≥ 18 years) and lung function (percent predicted forced 
expiratory volume in 1-second [ppFEV1] ≥ 70%, 41-69%, ≤ 40%). Descriptive analyses 
were conducted. Results: Data for 523 patients were included. Baseline mean 
± SD age was 24.8 ± 9.5 years and mean ± SD ppFEV1 was 67.1 ± 22.9%. During 
disease activity and lab measurements. Results: 106 papers met our inclusion 
criteria. Studies were published between 2003 and 2015 and mostly from Europe; 
39 included patients starting etanercept, 36 included patients starting rituximab 
and 32 patients starting tocilizumab. Mean age ranged between 42.9 and 63.3 years, 
78.2% were female. The drugs were given in combination with methotrexate and/or 
other traditional DMARDs in over two thirds of the studies. Mean disease duration 
varied between 4 and 17.5 years, baseline disease activity 28 scores between 4.3 and 
7.0, and baseline health assessment questionnaire values between 1 and 2.9. The 
mean percentage of rheumatoid-factor positive patients was 76.4%. Reporting of 
comorbidities and smoking status was generally poor, with only few studies provid-
ing detailed data. cOnclusiOns: This systematic review of data from observational 
studies and clinical databases indicates that the characteristics of RA patients start-
ing biological DMARDs outside clinical trials in the real world varied widely. These 
observational data will now be compared with clinical trial data but it seems likely 
that some patient groups were not well represented in the trials.
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effectiveneSS of A RefeRRAl PRogRAM foR eARlY ARthRitiS diAgnoSiS 
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Objectives: Early diagnosis and treatment of inflammatory arthritis can limit 
the impact of disease outcomes. We aimed to evaluate the effectiveness of a 
referral program on the identification of patients with suspected inflammatory 
arthritis. MethOds: SIARA (Referral Strategies and Disease Education Impact 
on Diagnosis and Referral of Axial Spondyloarthritis and Rheumatoid Arthritis 
Patients) is an observational prospective, randomized (by clusters of primary care 
centers) study to analyze the impact of Referral Support Actions (RSA) consisting 
of physician educational sessions about the disease and implementation of referral 
recommendations. The participating primary care centers (n= 24) were randomly 
assigned to RSA or control group (with no intervention). Both RSA and control 
groups identified and referred patients with suspected inflammatory arthritis to 
the rheumatology unit of the reference hospital (n= 6). The main studied outcome 
is the correct diagnosis of inflammatory arthritis / rheumatoid arthritis confirmed 
by the rheumatologist of the reference hospital. Results: A total of 125 patients 
were referred to a rheumatologist (considering 4 hospitals): 61 RSA patients and 
64 control patients. Mean age was 48.9 years (range: 19-73) and 88.8% were female 
(differences not statistically significant between groups). About 14.8% (n= 9) of RSA 
patients and 4.7% (n= 3) of controls had a confirmed diagnosis of arthritis (any 
type) by the rheumatologist (OR= 3.5; 95%CI, 0.9-13.7; Chi-square p= 0.056). Rate 
of confirmed rheumatoid arthritis was 4.9% in RSA patients and 1.6% in controls 
(p= 0.287). The majority of the patients (82.0%) were referred in the 4 months after 
educational session (month 3:63.9%; month 6:96.7%). cOnclusiOns: Although the 
study results still lack statistical significance, this preliminary data already suggests 
a positive impact of a referral program on the early identification of inflammatory 
arthritis, especially after the first few months. This should be further analyzed and 
considered by healthcare deciders in order to improve health outcomes in inflam-
matory arthritis.
PMS137
A web-bASed SuRveY to inveStigAte the extent of AwAReneSS And 
undeRStAnding foR bioSiMilAR AMong JAPAneSe PhYSiciAnS And 
PhARMAciStS
Tanabe K, Sugimoto N, Fujimoto Y
Pfizer Japan Inc, Tokyo, Japan
Objectives: Several biosimilar products have been developed and marketed in 
Japan. However, the degree of understanding of biosimilars among healthcare pro-
fessionals is uncertain. The objective of this study was to investigate the extent 
of awareness and understanding of biosimilars among Japanese physicians and 
pharmacists. MethOds: This was a non-interventional, web-based survey con-
ducted in May 2015. Japanese physicians (rheumatologists/oncologists) and phar-
macists voluntarily participated and provided their thoughts via questionnaires. 
Rheumatologists who have seen > = 30 rheumatoid arthritis patients/month on aver-
age and have prescribed biologics (Remicade/Humira, etc.) to at least one patient, 
and oncologists who have seen > = 30 cancer patients/year with use of biologics 
(Rituxan/Avastin/Herceptin, etc.) to at least one patient were eligible. Results: Of 
screened physicians, about 35% have never heard of “biosimilar”, whereas 96% of 
pharmacists were aware of “biosimilar”. One hundred rheumatologists, 120 oncolo-
gists (30 each for Hematology/Breast/Gastroenterology/Respiratory) and 90 pharma-
cists who met the criteria and were aware of biosimilar were analyzed for a further 
questionnaire. 73% of rheumatologists and 82% of oncologists recognized that 
biosimilars “are relatively less expensive” and 62% of physicians simply answered 
“subsequent product/generic”. 58% of rheumatologists showed an intention to pre-
scribe future biosimilars, whereas 73% of oncologists showed prescription intention. 
The main reason behind this was “reduction of burden on patients”, followed by 
“confirmed similarity in efficacy/safety”. Physicians with little intention to prescribe 
biosimilars showed strong concerns for similarity to the innovator (> 70%) and insuf-
ficient clinical data in efficacy/safety perspectives. Similarities in clinical efficacy/
safety were more emphasized compared to structural and functional similarities 
in biosimilar development pathways. cOnclusiOns: Awareness of biosimilars 
amongst Japanese physicians was still low with a strong leaning toward burden on 
patients and sufficient clinical data to confirm the similarity. Providing learning 
opportunities for general tenets of biosimilarity and its development pathways are 
vital to increase public recognition of biosimilars.
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01/01/2009 and 31/01/2013 were identified in The Health Improvement Network 
(THIN) database. Patients were excluded if they had history of; chronic kidney dis-
ease stage 4/5, cancer, neuropathic pain, sciatica/radiculopathy, diabetes, back pain 
or a prior prescription for a study drug. Patients were classified as responders if they 
were either “cured” (discontinued treatment) or stable (remained on treatment), 
or a non-responder if they were referred to a pain clinic or switched to a CYP2D6-
independent analgesic. Multivariate logistic regression was used to identify the pre-
dictors of response and estimate the influence of CYP2D6-inhibitors. Results: The 
cohort consisted of 43,632 patients: 90.8% were responders, and CYP2D6-inhibiting 
drugs were prescribed to 33.8% of the cohort. Almost three times as many patients 
failed to respond in those prescribed a CYP2D6-inhibitor (16% vs. 6%). Controlling 
for medication, demographics and co-morbidities the logistic regression indicated 
the odds of responding for those with a CYP2D6-inhibiting co-prescription were 
39% lower than those without a co-prescription for a CYP2D6 inhibiting drug (OR= 
0.61, 95% CI 0.57 to 0.66). cOnclusiOns: Chronic non-malignant pain patients 
with a co-prescription for a CYP2D6-inhibiting medication were significantly less 
likely to respond to analgesia treatment and therefore received suboptimal pain 
management.
PSY6
ReAl-woRld evidence of iRon chelAtion theRAPY in tRAnSfuSion-
dePendent MdS PAtientS: A PoRtugueSe hoSPitAl RegiStRY
Rodrigues S1, Almeida A1, Viriato D2, Antunes M3
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Objectives: Transfusional iron overload is common among patients with myelo-
dysplastic syndromes (MDS) receiving red blood cell (RBC) transfusions. Emerging 
evidence indicates that iron chelation therapy (ICT) could improve health outcomes 
in MDS patients with low/intermediate-1 IPSS risk. This study aimed to investigate 
clinical evolution and transfusion dependency of MDS patients under ICT with 
deferasirox, in clinical practice. MethOds: This was a retrospective analysis of a 
hospital registry of MDS patients followed-up by imunohemotherapy. Longitudinal 
data records were aggregated in 3 months periods. Exploratory analysis was per-
formed to characterize patients. Generalized Estimation Equation models were 
used to estimate the effect of time on average ferritin levels and RBC transfusions, 
controlled by patient’s initial conditions and deferasirox dose. Generalized Linear 
Mixed-effects Models were estimated to assess individualized evolution patterns. 
In modelling only patients chelated for ≥ 6 months were considered. Results: A 
total of 877 records of 17 MDS patients (53% male), classified as low risk at diagnosis, 
were included in the analysis. Median ages at diagnosis, beginning of RBC transfu-
sions and beginning of ICT were 71, 74 and 77, respectively. Patients had received 
an average of 51.6±26.2 RBC units before ICT. Average values of clinical param-
eters were calculated for each patient. Sample medians were: ferritin 3674.3ng/mL, 
hemoglobin 8.2g/dL, alkaline phosphatase 91.3UI/L, gamma-glutamyl transferase 
0.4UI/L, aspartate aminotransferase 27.0UI/L, alanine aminotransferase 42.9UI/L and 
blood creatinine 0.9mg/dL. From the 8 patients chelated ≥ 6 months: 6 presented 
a decrease on ferritin levels and 4 presented a decrease in RBC transfusions (one 
reaching transfusional independence), over time. Marginal models demonstrated 
that average ferritin levels and number of RBC decrease with time (β = -141.9 p= 0.008; 
β = -0.043 p= 0.001, respectively). cOnclusiOns: Analysis of real-world data from 
a Portuguese registry of transfusion-dependent MDS patients chelated with def-
erasiforx, for ≥ 6month, indicated that both ferritin levels and RBC transfusions 
tend to decrease with time.
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guillAin-bARRe SYndRoMe: clinicAl PReSentAtion, tReAtMent PAtteRn 
And outcoMe
Vijayanarayana K1, Beena AS1, Anuvrinda C1, Bhumika M1, Sreedharan N1,  
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Objectives: To study the clinical presentations, treatment pattern and outcome of 
patients diagnosed with Guillain-Barre Syndrome (GBS). MethOds: A retrospective 
observational study, carried out in a tertiary care teaching hospital. Data of patients 
diagnosed with GBS and admitted to ICUs, medical wards and neurological wards 
from 2008 to 2013, was collected from medical records department (MRD) registry 
using ICD-10 code G61.0 Results: During the study period total 130 patients were 
diagnosed with GBS. The mean age of the study population was 35.3±20.7 years 
(mean±SD) and 55.4% (n= 72) patients were male. Hospital admissions due to GBS 
showed a marked escalation yearly from 2008 to 2013. 48.4% (n= 63) of patients 
reported flu like syndrome along with loose stools one week prior to GBS onset. The 
main clinical manifestations of GBS, bilateral ascending weakness and areflexia 
was seen in 69.2% of patients. Respiratory paralysis is the major cause of mortality 
in GBS patients and was present in 17.7% (n= 23) of the patients. Among the study 
population 49.2% (n= 64) of patients received intravenous Ig (IVIg) therapy and 11.5% 
(n= 15) of patients underwent plasmapheresis. Other supportive therapies included 
were physiotherapy/occupational therapy (13.8%) and corticosteroid therapy (10.8%). 
Due to high economic burden 14.6% (n= 19) of patients denied all treatments. Among 
the patients who received IVIg therapy, 4.7% showed complete recovery and 82.8% 
showed significant improvement whereas patients who received plasmapheresis, 
85.7% showed significant improvement. The mortality rate in patients who received 
IVIg was 1.6% whereas in plasmapheresis was 7.1%. cOnclusiOns: Both IVIg and 
plasmapheresis treatments showed significant improvement within 3 weeks. In 
our study setting, IVIg was the preferred treatment option due to low side effect 
profile and ease of administration however cost of treatment is higher compared 
to plasmapheresis. Plasmapheresis was associated with complications such as BP, 
HR fluctuations.
the 12-month baseline period, 26% of patients experienced 1 PEx, 15% had 2, and 
20% had ≥ 3. Corresponding proportions over a mean of 27 months of follow-up 
were 16%, 12%, and 52%. The mean PEx rate rose from 1.3 to 1.6/patient-year 
from baseline to follow-up. In the follow-up period, proportions of patients with 
at least 1 PEx and rates of PEx were higher among adults (84%; 1.7/patient-year) 
versus adolescents (70%; 1.5/patient-year) and for patients in the severe ppFEV1 
group (86%; 2.0/patient-year) compared with the mild group (70%; 1.1/patient-
year). Among patients with PEx, 61% required inpatient hospitalization (mean ± 
SD length of stay, 13.3 ± 7.4 days) and 73% required either hospitalization or IV 
antibiotics. cOnclusiOns: The majority of patients with CF homozygous for the 
F508del CFTR gene mutation experience at least one PEx annually and many PEx 
are associated with lengthy hospitalizations. The rates of PEx increase over time 
and are highest for adults and for those in the most severe lung function group, 
consistent with a progressive disease.
PSY3
efficAcY of the MicA AntibodY foR tRAnSPlAnt PAtientS
MO J
National Evidence-based Healthcare Collaborating Agency, SEOUL, South Korea
Objectives: MICA antibody identification is a test performed on transplant 
patients to check for the presence of donor-specific MICA for the purpose of pre-
dicting the incidence of organ rejection among transplant patients. The purpose 
of this assessment was to evaluate the effectiveness. MethOds: The literature 
search was performed using 8domestic research databases and 3core databases. A 
total of 9papers that remained. Each of the stages from literature search to applica-
tion of selection criteria and data extraction was independently by 2researcher. 
The SIGN was used for the quality assessment. Results: There were 5studies 
reporting on the medical results of kidney transplant patients. 2of the studies 
reported no significant differences in the graft survival rate and incidence of organ 
rejection(p= .67). There were 3studies reporting of heart transplant patients. There 
was one study reporting of lung transplant patients. The incidence of organ rejec-
tion was reported to be 42.0%(p= ns). cOnclusiOns: MICA Identification lacked 
clinical effectiveness for the following reasons: i)there were no significant differ-
ences in the graft survival rate and incidence of organ rejection; ii)it is difficult to 
determine whether the different results for the graft survival rate and incidence 
of organ rejection reported.
PSY4
A SYSteMAtic liteRAtuRe Review And netwoRk MetA-AnAlYSiS of 
cAPSAicin 8% PAtch veRSuS oRAl neuRoPAthic PAin MedicAtionS foR 
the tReAtMent of PAinful diAbetic PeRiPheRAl neuRoPAthY
van Nooten FE1, Charokopou M2, Poole C3, Treur M2
1Astellas Pharma BV, Leiden, The Netherlands, 2Pharmerit International, Rotterdam,  
The Netherlands, 3Astellas Pharma Europe Ltd, Chertsey, UK
Objectives: The efficacy and safety of capsaicin 8% patch (Qutenza) for treat-
ing painful diabetic peripheral neuropathy (PDPN) has recently been studied but 
direct comparison with other treatments is lacking. The objective was to obtain 
estimates of the relative efficacy and safety of oral treatments for PDPN and cap-
saicin 8% patch. MethOds: A systematic literature review (SLR) and network 
meta-analysis (NMA) were conducted. The SLR collated data from all published 
randomized controlled trials (RCTs) comparing either pregabalin, duloxetine, 
amitryptiline or gabapentin. Efficacy data for capsaicin 8% patch was obtained 
from 12-week placebo-controlled RCT (STEP) and a 12-month open-label ran-
domized study versus standard of care (PACE). Electronic databases (Embase, 
Medline, CRD-Dare and Cochrane) were searched up to February 2014. Search 
results were screened, eligible studies were assessed for risk of bias and data 
were extracted. Efficacy outcomes selected for Bayesian NMA (WinBUGS v.1.4) 
included responder status (≥ 30%/ ≥ 50% reduction in pain) and absolute change 
in pain score from baseline. Safety endpoints included nausea, diarrhoea, som-
nolence and dizziness. Results: Out of the 400 unique records identified, 24 
were eligible for inclusion in the review. Eight studies were included in the NMA 
for ≥ 30% pain reduction, 10 for ≥ 50% pain reduction, and 11 reporting pain score 
change. No significant differences were observed between treatments regard-
ing either responder rate based on ≥ 30%/ ≥ 50% pain reduction or pain score 
change from baseline. Scenario analyses considering different dosing regimens 
of pregabalin and duloxetine, different definitions of clinical endpoints and inclu-
sion of PACE trial data did not significantly change the results. The capsaicin 8% 
patch exhibited none of the investigated safety events, whereas all orals reported 
dose-dependent side-effects. cOnclusiOns: This NMA found that capsaicin 
8% patch, pregabalin, duloxetine, and gabapentin do not have different efficacy 
profiles for PDPN; however, capsaicin 8% patch exhibits fewer systemic adverse 
events.
PSY5
how ARe PAin tReAtMent ReSPonSe RAteS in PRiMARY cARe influenced 
bY co-PReScRiPtion of cYP2d6 inhibitoRS?
Pockett RD1, O’Leary CJ2, Anderson P3, Nasser A2, Winfield TG3, Ansell D2
1Swansea Centre for Health Economics, Swansea, UK, 2IMS Health, London, UK, 3Swansea 
University, Swansea, UK
Objectives: To determine the rates of co-prescription of CYP2D6-inhibiting medi-
cations with pain medication and the impact on response rates to pain medications, 
in the UK primary care setting. MethOds: Codeine and tramadol are prodrugs 
requiring activation by the CYP2D6 enzyme. These drugs may have limited effective-
ness when co-prescribed with other medications known to inhibit the CYP2D6 path-
way. This contrasts with CYP2D6-independent analgesia, e.g. buprenorphine, which 
do not require CYP2D6 activation. We identified the co-prescription of three study 
pain medications; buprenorphine, codeine and tramadol with CYP2D6-inhibiting 
drugs including amitriptyline and fluoxetine. Patients aged ≥ 18 years with chronic 
non-malignant pain and prescribed buprenorphine, codeine or tramadol between 
